Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

AJCC Cancer Staging Manual

2016 • 16,972 citations

Pathogen Recognition and Innate Immunity

2006 • 11,197 citations

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1982 • 10,605 citations

AJCC Cancer Staging Manual

2002 • 6,356 citations

Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8

2004 • 3,766 citations

Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA

2004 • 3,325 citations

Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway

2002 • 2,438 citations

AJCC Cancer Staging Manual. 6th ed

2002 • 2,374 citations

Recognition of single-stranded RNA viruses by Toll-like receptor 7

2004 • 1,777 citations

Cancer/testis antigens, gametogenesis and cancer

2005 • 1,541 citations

Interferons, immunity and cancer immunoediting

2006 • 1,497 citations

Interferon-α and Interleukin-12 Are Induced Differentially by Toll-like Receptor 7 Ligands in Human Blood Dendritic Cell Subsets

2002 • 461 citations

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

2004 • 446 citations

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

2002 • 378 citations

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

2002 • 374 citations

Triggering TLR signaling in vaccination

2005 • 359 citations

NY‐ESO‐1: Review of an Immunogenic Tumor Antigen

2006 • 354 citations

Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity

2006 • 352 citations

Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells

2007 • 351 citations

Toll-like receptors and dendritic cells: for whom the bug tolls

2004 • 334 citations

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8⁺T cell responses in nonhuman primates

2005 • 329 citations

Treatment of genital warts with an immune-response modifier (imiquimod)

1998 • 308 citations

Imiquimod, a Topical Immune Response Modifier, Induces Migration of Langerhans Cells11The authors have declared a conflict of interest.

2000 • 295 citations

Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses

2003 • 292 citations

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

2007 • 290 citations

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

2004 • 288 citations

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

2006 • 279 citations

Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides

2006 • 273 citations

A Randomized, Controlled, Molecular Study of Condylomata Acuminata Clearance during Treatment with Imiquimod

1998 • 255 citations

Human Langerhans Cells Express a Specific TLR Profile and Differentially Respond to Viruses and Gram-Positive Bacteria

2006 • 250 citations

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe

2005 • 235 citations

Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage

2006 • 229 citations

Toll-like receptors and acquired immunity

2004 • 207 citations

Identification and Characterization of pDC-Like Cells in Normal Mouse Skin and Melanomas Treated with Imiquimod

2004 • 205 citations

The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity

2006 • 205 citations

Innate immunity — cross-talk with adaptive immunity through pattern recognition receptors and cytokines

2006 • 197 citations

Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients

2004 • 182 citations

Disease-Independent Skin Recruitment and Activation of Plasmacytoid Predendritic Cells Following Imiquimod Treatment

2005 • 176 citations

Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation

2003 • 168 citations

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

2005 • 155 citations

Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod

2005 • 154 citations

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

2008 • 153 citations

The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.

2004 • 122 citations

Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors.

2007 • 113 citations

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

2004 • 106 citations

The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a Recombinant Listeria monocytogenes Vaccine

2005 • 84 citations

Randomized, Single-Blind, Placebo-Controlled Studyof Topical Application of the Immune Response ModulatorResiquimod in HealthyAdults

2003 • 72 citations

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA

2004 • 66 citations

NY‐ESO‐1/LAGE‐1 coexpression with MAGE‐A cancer/testis antigens: A tissue microarray study

2005 • 62 citations

Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine

2005 • 58 citations

Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma

2005 • 32 citations

Prolonged Imiquimod Treatment and Graft-versus-Host Reaction: Histological Mimicry in the Skin Infiltration Pattern of the Monocyte-Macrophage-Dendrocyte Lineage

2003 • 14 citations

A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients

2005 • 10 citations